Aktuelle Wissenschafts-News

B- und T-Zell-Analyse zur Vorhersage der Rituximab-Response

Rosenzwajg M, Languille E, Debiec H et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int 2017; 92(1): 227-37 mehr...

Feinstaubbelastung erhöht die CKD-Inzidenz

Bowe B, Xie Y, Li T et al. Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 2018; 29(1): 218-30 mehr...

Arterielle Katheterembolisation bei ADPKD

Suwabe T, Ubara Y, Sekine A et al. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease. NDT 2017; 32(7): 1176-83 mehr...

Endokarditis bei CKD-Patienten

Chaudry MS, Carlson N, Gislason GH et al. Risk of Infective Endocarditis in Patients with End Stage Kidney Disease. Clin JASN 2017 Nov; 12(11): 14-1822 mehr...

Eine Fistelanlage vor dem Dialysebeginn verlangsamt den weiteren GFR-Abfall

Sumida K, Molnar MZ, Potukuchi PK et al. Association between vascular access creation and deceleration of estimated glomerular filtration rate decline in late-stage chronic kidney disease patients transitioning to end-stage renal disease. NDT 2017; 32(8): 1330-7 mehr...

Subjektive Wahrnehmung einer intensiven Blutdruckeinstellung

Berlowitz DR, Foy CG, Kazis LE et al. SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. NEJM 2017; 377(8): 733-44 mehr...

Epidemiologie von Rehospitalisierungen bei HD-Patienten

Chan L, Chauhan K, Poojary P et al. National Estimates of 30-Day Unplanned Readmissions of Patients on Maintenance Hemodialysis. Clin JASN 2017; 12(10): 1652-62 mehr...

Subgruppenanalyse der LEADER-Studie

Mann JFE, Ørsted DD, Brown-Frandsen K et al.; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. NEJM 2017; 377 (9): 839-48 mehr...

Canagliflozin bei Typ-2-Diabetikern

Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. NEJM 2017; 377(7): 644-57 mehr...